Group 1 - The medical beauty sector experienced a decline of 0.27% compared to the previous trading day, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3876.37, up 0.16%, while the Shenzhen Component Index closed at 13053.98, down 1.29% [1] - The net inflow of main funds into the medical beauty sector was 253,500 yuan, while retail investors saw a net outflow of 701,410 yuan [2] Group 2 - The sector saw a net inflow of 676,060 yuan from speculative funds [2] - Detailed fund flow data for individual stocks in the medical beauty sector is available in the accompanying table [2]

Core Viewpoint - The collagen market is undergoing significant changes with the approval of new products from Chongshan Bio and Aibai Rui, expanding the competitive landscape in the animal-derived collagen sector. The focus is shifting towards differentiation in terms of cost-effectiveness, brand recognition, product safety, and efficacy as the market becomes increasingly crowded [1][2]. Group 1: New Product Approvals - Chongshan Bio's new product is the world's first collagen implant with a concentration of 45mg/ml, aiming to establish a strong product image through high concentration [2]. - Aibai Rui's new product targets specific needs by improving cheek smoothness, attempting to create a niche in the market despite similarities to existing products [4]. Group 2: Market Dynamics - The animal-derived collagen market has formed an "eight strong" competitive landscape, with established players like Shuangmei Bio leading the market due to their early entry and established brand recognition [6]. - New entrants are focusing on differentiation strategies, such as high-quality ingredients and innovative product forms, to compete effectively [6]. Group 3: Growth of Recombinant Collagen - The recombinant collagen market is experiencing rapid growth, with a projected compound annual growth rate (CAGR) of 41.4% from 2023 to 2027, surpassing the 27.7% CAGR of animal-derived collagen [8]. - The market size for recombinant collagen products in 2023 is estimated at 28.63 billion yuan, slightly below the 29.79 billion yuan for animal-derived collagen, indicating a shift in consumer preference towards recombinant options [8]. Group 4: Competitive Landscape and Future Outlook - The approval of new recombinant collagen products is intensifying competition, with companies like Jinjian Bio and others entering the market, challenging the previous dominance of Jinbo Bio [9]. - The future of the collagen market will likely see increased competition, with a focus on cost-effectiveness, brand strength, and product efficacy becoming critical for success [12].

Group 1 - The medical beauty sector experienced a decline of 2.27% on December 15, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3867.92, down 0.55%, while the Shenzhen Component Index closed at 13112.09, down 1.1% [1] - A detailed table of individual stock performance in the medical beauty sector is provided [1] Group 2 - In terms of capital flow, the medical beauty sector saw a net outflow of 48.24 million yuan from main funds, while retail investors contributed a net inflow of 53.44 million yuan [2] - The net outflow from speculative funds was 5.20 million yuan [2] - A detailed table of capital flow for individual stocks in the medical beauty sector is included [2]

Group 1 - The core point of the article is the announcement by Jinbo Bio regarding the change in its sponsoring representative due to the work shift of the previous representative, Yao Yao [2] - CITIC Securities has appointed Zhong Shan to replace Yao Yao as the sponsoring representative for the company's ongoing supervision and the stock issuance project for specific targets in 2025 [2] - The ongoing supervision sponsoring representatives have been changed to Deng Jun and Zhong Shan [2]

证券时报·数据宝统计显示，锦波生物今日收盘价为275.50元，上涨9.02%，日换手率为7.01%，成交额 为10.40亿元，近5日该股累计上涨20.67%。 据天眼查APP显示，山西锦波生物医药股份有限公司成立于2008年03月28日，注册资本11506.534万人 民币。（数据宝） 锦波生物（920982）12月12日大宗交易平台出现一笔成交，成交量1.46万股，成交金额478.88万元，大 宗交易成交价为328.00元，相对今日收盘价溢价19.06%。该笔交易的买方营业部为中信证券股份有限公 司大连高新园区证券营业部，卖方营业部为华泰证券股份有限公司南京长江路证券营业部。 进一步统计，近1个月内该股累计发生6笔大宗交易，合计成交金额为3240.88万元。 | 成交量 | 成交金额 | 成交价格 | 相对当日收 盘价折溢价 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | （%） | | | | 1.46 | 478.88 | 328.00 | 19.06 | 中信证券股份有限公司 大连高新园区证券营 ...

据天眼查APP显示，山西锦波生物医药股份有限公司成立于2008年03月28日，注册资本11506.534万人 民币。（数据宝） 12月11日锦波生物大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收 盘价折溢价 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | （%） | | | | 2.00 | 638.00 | 319.00 | 26.24 | 中信证券股份有限公司 大连高新园区证券营业 | 华泰证券股份有限公司 南京长江路证券营业部 | | | | | | 部 | | （文章来源：证券时报网） 锦波生物（920982）12月11日大宗交易平台出现一笔成交，成交量2.00万股，成交金额638.00万元，大 宗交易成交价为319.00元，相对今日收盘价溢价26.24%。该笔交易的买方营业部为中信证券股份有限公 司大连高新园区证券营业部，卖方营业部为华泰证券股份有限公司南京长江路证券营业部。 进一步统计，近1个月内该股累计发生5笔大宗交易，合计成交金额为2762.00万元。 证券时报·数 ...

Group 1 - The medical beauty sector increased by 1.0% on December 10, with Jinbo Biological leading the gains [1] - The Shanghai Composite Index closed at 3900.5, down 0.23%, while the Shenzhen Component Index closed at 13316.42, up 0.29% [1] - A table detailing the individual stock performance in the medical beauty sector is provided [1] Group 2 - In terms of capital flow, the medical beauty sector experienced a net outflow of 2.1769 million yuan from main funds, while retail funds saw a net inflow of 6.8531 million yuan [2] - Retail investors had a net outflow of 4.6763 million yuan [2] - A table showing the capital flow for individual stocks in the medical beauty sector is included [2]

Core Viewpoint - Jinbo Bio is leveraging its first-mover advantage and original innovation capabilities to establish a "license barrier" in the industry, aiming to become a world-class technology-driven bio-materials enterprise amidst increasing competition [2]. Group 1: Product Development and Innovation - Jinbo Bio has made significant breakthroughs with its core products, including the first international discovery and analysis of the atomic structure of type III collagen, which features a flexible helical structure at 164.88° [3]. - The company has developed the first original bio-material with independent intellectual property rights in China, including a broad-spectrum anti-HPV bio-protein and a multi-peptide drug for COVID-19 [3][4]. - Jinbo Bio holds three class III medical device registration certificates for recombinant human collagen, covering all dosage forms including freeze-dried fibers, solutions, and gels [3][7]. Group 2: Research and Development - The company has completed 12 projects on the atomic structure of human collagen, aiming to develop more innovative and differentiated products [4]. - Jinbo Bio has developed the "AI Collagen Brain System" to enhance research efficiency and reliability, collaborating with several universities and research institutions to establish research platforms [5]. Group 3: Industry Standards and Market Position - Jinbo Bio has participated in the formulation of multiple industry standards and is expanding into international standards, enhancing its influence in the global biopharmaceutical field [6]. - The company has maintained a leading position in the recombinant human collagen sector, despite increased competition, by leveraging its established clinical data and distribution networks [7]. Group 4: Strategic Development and Future Plans - Jinbo Bio is constructing a recombinant human collagen industrial park in collaboration with the Shanxi Comprehensive Reform Demonstration Zone to attract upstream and downstream enterprises [8]. - The company plans to enhance its product matrix and distribution channels, focusing on innovative product development and expanding market coverage through partnerships and brand promotion [8][9]. - Jinbo Bio aims to become an internationally leading bio-materials enterprise by deepening basic research and applying new technologies in the healthcare sector [9].

锦波生物（920982）12月9日大宗交易平台出现一笔成交，成交量2.50万股，成交金额750.00万元，大宗 交易成交价为300.00元，相对今日收盘价溢价28.58%。该笔交易的买方营业部为中信证券股份有限公司 大连高新园区证券营业部，卖方营业部为华泰证券股份有限公司南京长江路证券营业部。 进一步统计，近1个月内该股累计发生4笔大宗交易，合计成交金额为2124.00万元。 证券时报·数据宝统计显示，锦波生物今日收盘价为233.31元，上涨0.62%，日换手率为1.64%，成交额 为2.11亿元，近5日该股累计上涨4.42%。（数据宝） 12月9日锦波生物大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收 盘价折溢价 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | | | | | | | | （%） | | | | 2.50 | 750.00 | 300.00 | 28.58 | 中信证券股份有限公司 大连高新园区证券营业 | 华泰证券股份有限公司 南京长江路证券营业部 | | | ...

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前核实。据此操作，风险自担。 每日经济新闻 （记者 曾健辉） 每经讯，2025年12月9日，北交所上市公司锦波生物（920982，收盘价：233.31元）发生一笔大宗交易，成交价300元/股，成交 数量2.5万股，成交金额750万元，溢价28.58%。买入营业部是中信证券股份有限公司大连高新园区证券营业部，卖出营业部是 华泰证券股份有限公司南京长江路证券营业部。 ...